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Dihydropteroate synthase (DHPS) mutations in Pneumocystis jiroveci have been associated epidemiologically
with resistance to sulfamethoxazole (SMX). Since P. jiroveci cannot be cultured, inherent drug resistance
cannot be measured. This study explores the effects of these mutations in a tractable model organism,
Saccharomyces cerevisiae. Based on the sequence conservation between the DHPS enzymes of P. jiroveci and S.
cerevisiae, together with the structural conservation of the three known DHPS structures, DHPS substitutions
commonly observed in P. jiroveci were reverse engineered into the S. cerevisiae DHPS. Those mutations, T597A
and P599S, can occur singly but are most commonly found together and are associated with SMX treatment
failure. Mutations encoding the corresponding changes in the S. cerevisiae dhps were made in a yeast centro-
mere vector, p414FYC, which encodes the native yeast DHPS as part of a trifunctional protein that also
includes the two enzymes upstream of DHPS in the folic acid synthesis pathway, dihydroneopterin aldolase and
2-amino-4-hydroxymethyl dihydropteridine pyrophosphokinase. A yeast strain with dhps deleted was employed
as the host strain, and transformants having DHPS activity were recovered. Mutants having both T597 and P599
substitutions had a requirement for p-aminobenzoic acid (PABA), consistent with resistance being associated
with altered substrate binding. These mutants could be adapted for growth in the absence of PABA, which
coincided with increased sulfa drug resistance. Upregulated PABA synthesis was thus implicated as a mech-
anism for sulfa drug resistance for mutants having two DHPS substitutions.
Dihydropteroate synthase (DHPS) is an important target for
antifolate compounds, such as sulfones and sulfonamides, in
both prokaryotic and eukaryotic microbes. Organisms treated
with sulfa drugs include pathogens, such as Pneumocystis ji-
roveci, Mycobacterium leprae, Neisseria meningitidis, and Plas-
modium falciparum. Numerous studies have reported that mu-
tations in the primary sequence of dhps are associated with
sulfa drug resistance (7, 10, 12, 18, 20, 22, 23, 32, 36, 38, 39).
The P. jiroveci mutant alleles map to a highly conserved se-
quence in DHPS that is associated with direct substrate contact
(1, 3, 14), although there is some controversy over whether
these influence drug treatment outcomes (2, 6, 15, 18, 19, 24,
26, 28, 33, 34). In vitro culture of P. jiroveci has not yet been
possible, nor has heterologous complementation of P. jiroveci
DHPS.
For other pathogens, the association between the efficacy of
antifolate drugs and genetic mutations in the dihydrofolate
reductase gene (dhfr) and dhps has been demonstrated using
model systems (11, 29, 31, 40). This would be particularly
useful for P. jiroveci, since there is no direct evidence that
mutant alleles identified in P. jiroveci dhps cause sulfa drug
resistance.
We have sought to better understand the relationship be-
tween DHPS changes and sulfa drug resistance by employing a
Saccharomyces cerevisiae model system. S. cerevisiae is a good
model for studying P. jiroveci DHPS because (i) both organ-
isms are fungi, (ii) both have trifunctional dihydroneopterin
aldolase (DHNA)–2-amino-4-hydroxymethyl dihydropteridine
pyrophosphokinase (PPPK)–DHPS enzymes, (iii) the DHPS
amino acid sequence alignments show 30% identity and 62%
similarity and DHNA-PPPK-DHPS (folic acid synthesis [FAS])
alignments show 37% identity and 64% similarity, (iv) the
organisms have identical sequences in the regions associated
with sulfamethoxazole (SMX) resistance (T597, R598, and P599
in S. cerevisiae; T517, R518, and P519 in P. jiroveci) (Fig. 1); (v)
the conservation rates of these residues across 75 published
DHPS species are 82, 80, and 99%, respectively, and (vi) the
residues map to the same region in the three known structures
of DHPS that have been solved to date (1, 3, 14).
Based on these high levels of identity and similarity, we
employed an allelic replacement strategy that utilized an S.
cerevisiae dhps knockout strain that was complemented by a
vector-encoded FAS, the product of the S. cerevisiae FOL1
gene. Residues in the wild-type FAS were mutated to give the
changes associated with SMX resistance. We report here the
phenotypic analysis and SMX resistance of various dhps alleles
implicated from epidemiological studies with SMX resistance.
MATERIALS AND METHODS
E. coli strains, growth media, and transformation. The bacterial strain em-
ployed for molecular cloning and plasmid amplification was Escherichia coli
strain MC1061 [araD139 (araABC-leu)7679 galU galK lacX74 rpsL hsdR (rK
mK) mcrB]. The growth medium utilized was 1 YT (0.5% [wt/vol] yeast
extract, 0.8% [wt/vol] tryptone, 0.5% [wt/vol] NaCl). Cells were made competent
by calcium chloride treatment, and transformants were selected on 1 YT  100
g of ampicillin/ml.
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Yeast strains, growth media, and transformation. The S. cerevisiae dhps
knockout strain used in this study, EHY1, has been described previously (4, 5,
16). EHY1 (MATa leu2-3,112 trp1 ura3-52 tup1 DHPS::LEU2) is a genomic dhps
knockout strain. The authenticity of the EHY1 knockout strain was confirmed by
molecular approaches and phenotypic analyses and was consistent with a specific
dhps deletion. The auxotrophic requirements and complementation of EHY1
were previously described (4). Media for the growth of yeast cells included
YEPD (1% [wt/vol] yeast extract [Difco], 2% [wt/vol] peptone, 2% [wt/vol]
D-glucose). Synthetic minimal medium (MM0) was 0.67% yeast nitrogen base
containing ammonium sulfate minus folic acid minus p-aminobenzoic acid
(PABA) (Bio 101) supplemented with 1% (wt/vol) D-glucose and 0.2% (wt/vol)
uracil.
Yeast transformants were obtained by the lithium acetate transformation
procedure (13), followed by growth and selection on complete synthetic medium
minus tryptophan. Complete synthetic medium was 0.67% yeast nitrogen base
(Difco) containing ammonium sulfate supplemented with 2% D-glucose, amino
acids, and adenine as described in the Cold Spring Harbor manual on yeast
genetics (8). This medium contained PABA (200 ng/ml) and folate (2 ng/ml).
Before being tested for SMX susceptibility, transformants were passaged on
MM0 six times.
Synthesis of mutant alleles implicated with sulfa drug resistance. The Quick-
change XL kit (Stratagene) was used to generate four mutant constructs from the
wild-type DHPS using oligonucleotides listed in Table 1. The wild-type construct
was designated TRP (T597, P599). The mutants were A597, P599 (designated
ARP); T597, S599 (designated TRS); and a double mutant, A597, S599 (designated
ARS). The fourth allele has not been reported clinically and was derived from
the ARS allele by a conservative change of A597 to V597. This yielded V597, S599
(designated VRS). This clone arose spontaneously during the mutagenesis pro-
FIG. 1. Alignment of DHPS sequences by using ClustalW. Displayed are sequences from E. coli (Ec), Mycobacterium tuberculosis (Mt), and
Staphylococcus aureus (Sa), whose structures have been solved, aligned to those of S. cerevisiae (Sc) and P. jiroveci (Pj). The asterisks indicate totally
conserved amino acids, the colons indicate very high conservation, and the dots indicate weak conservation. Amino acids associated with SMX
resistance in P. jiroveci DHPS (T3A and P3S) are highlighted and in boldface. Dashes represent gaps introduced by the alignment.
TABLE 1. Oligonucleotides used for site-directed mutagenesis
Clone Substitution Oligonucleotide no. Direction of priming Sequence (5 3 3)a
ARS A597, S599 146337 3 GGAGGGTGTTCTGCCAGGTCTAACTCTATTCAGGC
146338 4 GCCTGAATAGAGTTAGACCTGGCAGAACACCCTCC
TRS T597, S599 146339 3 GGAGGGTGTTCTACCAGGTCTAACTCTATTCAGGC
146340 4 GCCTGAATAGAGTTAGACCTGGCAGAACACCCTCC
ARP A597, P599 146341 3 CGTTGGAGGGTGTTCTGCCAGGCCTAACTCTATTC
146342 4 GAATAGAGTTAGGCCTGGCAGAACACCCTCCAACG
a Nucleotide substitutions are in boldface.
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cedure and was kept for its intrinsic interest. In order to validate the synthesis of
the mutant allele sequence, each construct was analyzed by DNA sequencing
using a Big Dye Terminator Cycle Sequencing Ready Reaction kit (Perkin-
Elmer). Each of the mutant constructs generated was transformed into EHY1
and plated onto complete synthetic medium minus tryptophan, and complement-
ing clones were selected.
Phenotypic analysis of S. cerevisiae transformants. Each transformant was
precultured in YEPD broth at 30°C. The cultures were harvested in log-phase
growth, washed with phosphate-buffered saline (PBS; 8% [wt/vol] NaCl, 0.2%
[wt/vol] KCl, 1.44% [wt/vol] Na2HPO4, 0.24% [wt/vol] KH2PO4, pH 7.4), and
normalized to a cell density of 6  106 CFU/ml (A595  0.1). A series of
twofold dilutions was made in a 96-well microtiter plate. One microliter of the
dilution series for each clone was spotted on solidified MM0. Alternatively, plates
were supplemented with various combinations of the folate biosynthetic pathway
end products, including methionine (20 g/ml), adenine (20 g/ml), histidine (20
g/ml), TMP (20 g/ml), and formyl-tetrahydrofolate (20 g/ml). In addition,
there was a detailed analysis of the affects of PABA that included supplementing
MM0 with PABA to achieve a final concentration of 0 to 10,000 ng/ml. The plates
were then incubated at 30°C for 3 to 5 days.
Determination of SMX resistances of prototrophs by drug diffusion assays. In
order to evaluate the relative sensitivity or resistance of each DHPS allele to
SMX, drug diffusion assays were performed with PABA supplementing the
molten medium at a final concentration ranging from 0 to 10,000 ng/ml. The
assays were performed in petri dishes 86 mm in diameter containing 25-ml
aliquots of MM0 solidified with 1.5% agar (Merck). A 6.5-mm-diameter hole was
made in the center of each agar plate. SMX (25 l at 100 mg/ml dissolved in
dimethyl sulfoxide [DMSO]) was loaded into the center and allowed to diffuse
through the plate for 	2 h. In control plates, 25 l of DMSO was also loaded into
the center and allowed to diffuse. Each experiment was performed in triplicate.
Each clone was precultured in YEPD broth at 30°C. The cultures were harvested
in log-phase growth, washed with PBS, and normalized to an A595 of 0.1. A
stainless-steel wire (2-mm diameter) was used to inoculate each clone radially
from the center of the agar plate. The plates were then incubated at 30°C.
Growth was evaluated after 3 to 5 days.
Determination of SMX resistances of prototrophs in broth cultures. In order
to accurately compare the growth rates (generation times) of the clones, the
growth of broth cultures in MM0 supplemented with 200 ng of pABA/ml (wt/vol)
(MM200) was monitored periodically over 180 h by turbidity measurements at
A595. Each clone was precultured in YEPD broth at 30°C. The cultures were
harvested in log-phase growth, washed with PBS, and normalized to an A595 of
0.1. These cells were then used to seed the growth cultures at an A595 of 0.02. The
MM200 broth was supplemented with SMX at 0 to 1,200 g/ml. Replicate ex-
periments were prepared in 96-well plates (2.2 ml deep), and the cultures were
finally aliquoted into four standard-size microtiter plates (Costar 3603) to a final
volume of 150 l. The plates were then incubated in a 30°C humidified incubator
and shaken at 1,000 rpm (with a 3-mm displacement). The turbidity was mea-
sured using a Multiskan Ascent microplate reader (Thermo Labsystems), and the
data were plotted using Graphpad PRISM software (version 3).
Determination of SMX resistance of naïve transformants in broth cultures. In
order to investigate whether elevated PABA levels could account for the in-
creased resistance observed in the adapted strains (prototrophs), the MICs of the
naïve transformants were determined in broth cultures. The medium for deter-
mination of the MIC was supplemented with PABA at levels up to 1,000 ng/ml.
SMX was then added in a range of concentrations (0 to 2,000 g/ml). After the
addition of PABA and SMX to the medium, the pH was adjusted to 7.1 to permit
the solubilization of SMX up to 2,000 g/ml and to eliminate pH differences
caused by the SMX and PABA. The upper limit of solubility of SMX is 2,000
g/ml in MM0 at pH 7.1. The DMSO concentration was constant at (0.5%).
Fresh (naïve) transformants were precultured in MM300 containing 2% glucose.
Cells were harvested in mid-log-phase growth, washed twice with 50 ml of PBS,
and normalized to an A595 of 1.0. Each strain (5 l of cells) was then seeded into
100 l of medium in a 96-well plate (Costar 3596). The cultures were grown at
30°C for up to 2 weeks. The seeding density for this experiment was 2.5-fold
higher than that of the liquid growth assays, which permitted limited growth of
ARS in MM0 (data not shown). The experiments were set up using a Qiagen
Rapidplate liquid-handling robot. Each experiment was performed in triplicate.
RESULTS
Construction of yeast strains with altered DHPS. The yeast
strain EHY1 had its chromosomal sequences encoding DHPS
deleted so that it no longer synthesized folates. However,
EHY1 could grow in the absence of added folate when trans-
formed with p414FYC, a centromere plasmid that encoded the
yeast DHNA-PPPK-DHPS trifunctional enzyme (FAS) under
the control of its native promoter (16). p414FYC derivatives,
altered only by mutations that produced amino acid substitu-
tions at T597 and P599 within DHPS to T597 and S599, A597 and
P599, A597 and S599, or V597 and S599 were prepared using
site-directed mutagenesis, confirmed by nucleotide sequence
analysis, and transformed into the EHY1 strain. Transfor-
mants were selected on yeast minimal medium in the absence
of added folate and tryptophan. Transformants were obtained
for each of the five constructs, indicating functional comple-
mentation by each altered DHPS enzyme. For convenience, we
shall refer to the five respective transformants as TRP, TRS,
ARP, ARS, and VRS.
PABA requirement of mutant transformants. The genera-
tion times of transformants expressing each mutant DHPS
gene were compared to determine if there were defects caused
by the mutant DHPS enzymes. Since SMX resistance assays
must be performed in the presence of low levels of PABA (27),
the transformants were adapted to low-PABA-folate medium
by serial passaging six times on MM0. The growth rates of the
strains were compared on minimal medium supplemented with
various levels of PABA ranging from 0 to 10,000 ng/ml (Fig. 2).
A significant defect was noted with respect to a requirement
for PABA by the mutants ARS and VRS. The TRP (wild-
type), ARP, and TRS transformants exhibited no significant
PABA requirement, while the double mutants, ARS and VRS,
exhibited significant PABA requirements, with VRS having
less PABA dependence. This indicated that the combined
changes of T597 and P599 caused a change in PABA binding or
condensation with 2-amino-4-hydroxy-6-hydroxymethyl-dihy-
dropteridine-pyrophosphate (H2PtPP).
SMX resistance of prototrophs by drug diffusion assays. We
evaluated the relative resistance of each transformant to SMX,
using drug diffusion assays following adaptation to PABA-free
minimal medium (MM0). MM0 was used initially to avoid the
competitive effect of PABA with the sulfa drugs. The results of
the replicates of drug diffusion assays in the presence of vari-
ous levels of PABA are shown in Fig. 3. In agreement with
previous studies (9), PABA and SMX were shown to compete
so that the degree of inhibition by SMX for each strain de-
creased with increasing concentrations of PABA. The smallest
inhibitory zones were observed with VRS and ARS, indicating
that the double substitutions confer the greatest SMX resis-
tance, and ARP and TRS, with single-amino-acid substitutions,
were more sensitive to growth inhibition than the wild type.
All transformants retained at least some SMX sensitivity,
probably reflecting the fact that DHPS is essential, and it might
not be possible to diverge to retain DHPS function and have
no sensitivity to SMX. It was possible to show that the inhibi-
tion of VRS and ARS, as well as TRP, converged to zero, or no
inhibition (complete resistance), when the PABA concentra-
tion was 	300 ng/ml, while the single-mutant alleles (ARP and
TRS) were still inhibited with PABA concentrations as high as
500 ng/ml (Fig. 3). By drug diffusion assays on solidified media,
the pattern of resistance to the action of SMX was VRS 	
ARS 	 TRP 	 TRS 	 ARP (most resistant to least resistant).
SMX resistances of prototrophs in broth cultures. In order
to precisely analyze whether the growth rate influenced drug
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resistance, growth assays were performed in MM200 broth sup-
plemented with increasing concentrations of SMX. This anal-
ysis produced MICs (Table 2) that agreed with those in the
drug diffusion assays (Fig. 3). VRS was highly resistant to
SMX, as strong growth was observed at the highest SMX
concentration tested, suggesting that the MIC was significantly
greater than 1,200 g/ml (i.e., 		1,200 g/ml). TRP and ARS
were significantly (but not completely) inhibited at 1,200 g/
ml, suggesting that the MICs were slightly greater than 1,200
g of SMX/ml (i.e., 	1,200 g/ml). By contrast, the single
mutants appeared to be considerably more sensitive (Table 2).
The growth rates of the adapted strains were also measured
in the presence of SMX and are shown in Fig. 4. In the absence
of SMX, VRS grew faster than all the other transformants,
with a generation time of 4 h. TRP, TRS, and ARP had similar
generation times of 5 h, and ARS had the longest generation
time, almost 6 h. With increasing concentrations of SMX, the
generation times of all transformants increased (Fig. 4), but
the effect on the generation time varied for each transformant.
The single mutant ARP became inhibited most quickly, fol-
lowed by the other single mutant, TRS. The resistance pattern
in Fig. 4 precisely matched that shown in Table 2. Likewise, the
consistency of profiles held with the other transformants. At
SMX concentrations of 600 g/ml, TRP had a shorter gen-
FIG. 2. Growth of transformants on minimal medium supplemented with various levels of PABA.
FIG. 3. Determination of SMX resistance by agar drug diffusion as-
say. SMX was solubilized in DMSO (100 mg/ml), and 25 l was applied
to the centers of agar plates. Additional plates were supplemented with
increasing concentrations of PABA. Transformants were harvested in
log-phase growth, washed in PBS, and normalized to 6  106 CFU/ml.
Each strain was then streaked radially from the center of the plate. The
plates were grown for 3 to 5 days, and the zones of inhibition for each
isolate, TRP, VRS, ARS, TRS, and ARP, were then scored. The results
are averages of triplicate experiments; error bars represent the standard
deviations of the means.
TABLE 2. MICs of SMX for yeast isolates grown in MM200
DHPS sequence Isolate MIC (g/ml)
A597, P599 ARP 150
T597, S599 TRS 600
A597, S599 ARS 	1,200
T597, P599 TRP 	1,200
V597, S599 VRS 		1,200
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eration time than the double mutant ARS. However, at SMX
concentrations of 	800 g/ml, the double mutant ARS grew
faster than TRP (Fig. 4). Therefore, ARS was more resistant
than TRP, as it had a shorter generation time and the MIC for
it was higher than that of TRP at high SMX concentrations
(data deduced from Fig. 4; cf. Table 2).
VRS, by comparison to all other transformants tested, was
the most resistant to SMX in MM100 (data not shown) and
MM200. The MIC was measured as 		1,200 g/ml (Table 2),
but it is obvious from Fig. 4 that at that level of SMX, it had a
generation time of 7 h.
SMX resistances of naïve transformants in broth cultures.
The MIC of SMX for each allele was plotted against the PABA
concentration. The data indicated that the resistance of the
single mutant ARP did not change significantly when the
PABA concentration was elevated. By contrast, the MICs of all
other mutants increased significantly with added PABA. The
rate of change differed for each clone, indicating that the
resistance of each allele was modulated by PABA to various
degrees. Specifically, the MIC for naïve ARS was lower than
those for TRS and the wild type (TRP) for all conditions
tested. This indicated that PABA was not the only factor that
led to the resistance of the passaged ARS prototroph (Fig. 3).
The MIC for VRS was observed to be highest, 2,000 g/ml,
when the PABA concentration was 100 ng/ml, reflecting the
lower requirement of VRS for PABA relative to the ARS
mutant. The MIC for TRP was 2,000 g/ml when the PABA
concentration was 150 g/ml.
DISCUSSION
Mutations in the DHPS gene that are implicated in sulfa
drug resistance were reverse engineered into vector-encoded
S. cerevisiae FAS (DHNA-PPPK-DHPS) and then transformed
into an S. cerevisiae strain having a dhps deleted, effectively
resulting in allelic replacement of the sequences encoding
DHPS. The two mutations found in the P. jiroveci DHPS gene
from patients for whom sulfa prophylaxis failed were sufficient
to cause a PABA auxotrophic requirement, as well as SMX
resistance, when engineered into S. cerevisiae DHPS (Fig. 1).
We conclude from this that such amino acid substitutions prob-
ably exert their effects either by reducing the affinity of DHPS
for sulfa drugs and for PABA or by affecting the catalysis of
condensation of sulfa drugs and PABA with H2PtPP. We have
also determined that the requirement for exogenous PABA is
much greater in primary transformants. After six passages,
yeast cells adapted to abrogate this PABA requirement. The
mechanism of this adaptation will be the subject of a future
publication (P. Iliades, M. M. Barraclough, S. R. Meshnick,
and I. G. Macreadie, unpublished data). This adaptive mech-
anism may involve increased biosynthesis of PABA. Upregu-
lated PABA synthesis has been suggested as a mechanism for
drug-resistant isolates of N. meningitides (17, 21, 37). In a yeast
model, it has been established that overexpression of the yeast
PABA synthase gene, ABZ1, results in resistance to sulfa drugs
(9). In order to ascertain whether adaptation (which possibly
alters PABA synthesis) was the only parameter affecting resis-
tance in our model, we determined the MICs for naïve strains
in a range of PABA concentrations. These data indicated that
PABA can confer increased SMX resistance on mutant strains.
However, the most striking observation was the divergent re-
sistance pattern among alleles (Fig. 5). If PABA was the only
factor effecting resistance, the change in resistance would be
expected to be uniform for each mutant. The divergent resis-
tance profiles observed demonstrate that PABA levels can
modulate the resistance of each mutant to various degrees.
The ARS mutant showed significantly lower resistance than
the ARS prototroph relative to the wild type, indicating that
PABA may not be the only parameter implicated in the in-
creased resistance of the adapted strains.
Importantly, our findings that the double-mutant constructs
were more resistant than the wild-type and single-mutant al-
leles are consistent with the epidemiological data that indicate
that double-mutant alleles predominate in frequency over the
single mutants (6, 18). If the same is true in P. jiroveci, then the
evolution of the double mutation occurred despite negative
selection for the first mutation.
Finally, we have found a mutant that was more resistant to
SMX than constructs with changes found naturally. The VRS
mutant, with the novel T597V and P599S DHPS substitutions,
was robust, having the lowest PABA dependence (of the dou-
ble mutants), the shortest generation times, and the highest
SMX resistance. Clearly there is an important interplay that
FIG. 4. Generation time of adapted transformants supplemented
with increasing concentrations of SMX in MM200. The results are
averages of four growth experiments.
FIG. 5. MICs for naïve transformants growing in MM0 supple-
mented with increasing concentrations of SMX and PABA. The results
are averages of three experiments. Note that the higher seeding density
for this experiment permitted the growth of all naïve transformants.
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appears to operate between PABA requirements and SMX
resistance. This mutant has fortunately not been observed clin-
ically, suggesting that in P. jiroveci it is disadvantageous or,
conversely, it might be just a matter of time before it appears.
The construction of S. cerevisiae strains with altered DHPS
sequences opens many new approaches to examining resis-
tance to sulfa drugs. It will now be possible to more precisely
assay the whole process of the emergence of sulfa drug resis-
tance in a model system that may have implications for under-
standing drug resistance in infectious organisms, using sophis-
ticated tools associated with S. cerevisiae genetics and
molecular biology. For example, using S. cerevisiae FAS mu-
tants (30) showed that sulfa drugs are converted to sulfa-
dihydropteroate (DHP) adducts that are growth inhibitory.
Thus, sulfa drugs exert an effect by more than one mechanism.
It will be interesting to compare the roles of SMX-DHP and
the depletion of folate production with different DHPS en-
zymes. We predict that VRS and ARS synthesize DHP in
preference to sulfa-DHP, and the ability of the double mutants
to do this is due to their discrimination between PABA and
sulfa drugs based on the binding affinity of DHPS. In addition,
there may be other factors affecting sulfa drug resistance, such
as the scavenging of nutrients (25, 35), PABA levels (9), and
folic acid levels (4).
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